SurModics Inc (SRDX)
Official siteMEDICAL DEVICES
Last updated: Nov 19, 2025 at 4:00 PM ET
SurModics Inc (SRDX) Financials: Revenue, Profit and Cash Flow
SurModics reported revenue of $126.08M for the fiscal year ended Sep 30, 2024, down 4.9% from the year before. That year, net income was -$11.54M with a net margin of -9.2%, operating cash flow was $248.00K and free cash flow was -$3.24M. The quarter ended Jun 30, 2025 had revenue of $29.57M and net income of -$5.32M.
Revenue and Margins
The operating margin was -4.5% in the fiscal year ended Sep 2024. Over the 9 years to Sep 2024, revenue grew from $61.90M, a compound annual rate of 8.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Sep 2024 | $126.08M | -4.9% | 73.8% | -4.5% | -9.2% |
| Sep 2023 | $132.58M | +32.6% | 81.2% | 3.9% | -1.2% |
| Sep 2022 | $99.95M | -4.9% | 79.6% | -22.1% | -27.3% |
| Sep 2021 | $105.14M | +10.8% | 83.7% | 6.4% | 4.0% |
| Sep 2020 | $94.86M | -5.2% | 83.9% | -1.3% | 1.2% |
| Sep 2019 | $100.08M | +23.0% | 86.4% | 6.5% | 7.6% |
| Sep 2018 | $81.34M | +11.2% | 82.8% | -10.8% | -5.5% |
| Sep 2017 | $73.11M | +91.6% | 84.4% | 9.7% | 5.4% |
| Sep 2016 | $38.16M | -38.3% | 71.4% | 44.2% | 26.2% |
| Sep 2015 | $61.90M | N/A | 86.1% | 30.8% | 19.3% |
Income Statement
In the fiscal year ended Sep 2024, the net loss widened from the year before. In the quarter ended Jun 2025, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $126.08M | $132.58M | $99.95M | $105.14M | $94.86M | $100.08M | $81.34M | $73.11M | $38.16M | $61.90M |
| Cost of revenue | $33.03M | $24.96M | $20.34M | $17.18M | $15.32M | $13.64M | $14.00M | $11.42M | $10.91M | $8.62M |
| Gross profit | $93.05M | $107.62M | $79.61M | $87.96M | $79.55M | $86.44M | $67.34M | $61.69M | $27.25M | $53.28M |
| Research and development | $38.36M | $46.59M | $50.61M | $46.73M | $50.19M | $53.77M | $48.86M | $31.82M | $18.50M | $16.16M |
| Operating income | -$5.64M | $5.15M | -$22.10M | $6.70M | -$1.25M | $6.47M | -$8.80M | $7.10M | $16.86M | $19.09M |
| Net income | -$11.54M | -$1.54M | -$27.27M | $4.24M | $1.12M | $7.59M | -$4.46M | $3.93M | $9.98M | $11.95M |
| EBITDA | $3.11M | $13.79M | -$12.81M | $14.60M | $5.29M | $13.93M | -$1.95M | $12.20M | $21.76M | $22.39M |
Quarterly
| Line item | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.57M | $28.09M | $29.92M | $33.23M | $30.34M | $31.96M | $30.55M | $27.97M | $52.48M | $27.20M | $24.93M | $25.99M |
| Gross profit | $20.99M | $20.25M | $22.50M | $24.55M | $21.89M | $24.86M | $21.75M | $20.93M | $45.56M | $21.46M | $19.67M | $20.39M |
| Operating income | -$5.24M | -$4.01M | -$2.48M | -$613.00K | -$5.37M | $659.00K | -$322.00K | -$2.45M | $21.41M | -$6.58M | -$7.23M | -$6.61M |
| Net income | -$5.32M | -$5.21M | -$3.65M | -$3.45M | -$7.55M | $247.00K | -$786.00K | $6.69M | $7.35M | -$7.73M | -$7.84M | -$14.73M |
Balance Sheet
As of Sep 2024, cash and equivalents exceeded long-term debt of $29.55M by $6.56M.
Annual
| Line item | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $178.56M | $185.73M | $158.36M | $194.59M | $168.76M | $159.87M | $164.13M | $136.59M | $132.89M | $98.71M |
| Current assets | $81.30M | $86.69M | $57.59M | $70.25M | $86.61M | $81.42M | $81.53M | $60.88M | $58.56M | $67.79M |
| Cash and equivalents | $36.12M | $41.42M | $19.00M | $31.15M | $30.79M | $30.36M | $23.32M | $16.53M | $24.99M | $55.59M |
| Total liabilities | $59.66M | $65.82M | $49.97M | $54.51M | $37.71M | $37.35M | $55.52M | $25.04M | $26.06M | $6.84M |
| Short-term debt | N/A | N/A | $10.00M | $10.00M | N/A | $3.20M | $11.04M | $1.75M | $925.00K | $305.00K |
| Long-term debt | $29.55M | $29.41M | $0 | N/A | N/A | N/A | $0 | $0 | $0 | $0 |
| Shareholder equity | $118.90M | $119.91M | $108.39M | $140.09M | $131.06M | $122.52M | $108.61M | $111.56M | $106.83M | $91.87M |
Quarterly
| Line item | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $169.82M | $163.21M | $163.74M | $178.56M | $177.41M | $182.81M | $180.24M | $185.73M | $188.90M | $166.16M | $169.75M | $158.36M |
| Total liabilities | $58.51M | $52.97M | $51.97M | $59.66M | $59.27M | $58.85M | $58.09M | $65.82M | $76.49M | $63.61M | $62.49M | $49.97M |
| Cash and equivalents | $26.28M | $29.18M | $30.14M | $36.12M | $24.30M | $33.03M | $23.36M | $41.42M | $44.58M | $19.18M | $26.43M | $19.00M |
| Shareholder equity | $111.31M | $110.25M | $111.77M | $118.90M | $118.14M | $123.95M | $122.15M | $119.91M | $112.41M | $102.55M | $107.26M | $108.39M |
Cash Flow
In the fiscal year ended Sep 2024, capital expenditures exceeded operating cash flow, leaving negative free cash flow.
Annual
| Line item | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $248.00K | $10.51M | -$17.22M | $15.39M | $14.01M | $8.04M | $34.05M | $14.05M | $25.17M | $15.07M |
| Capital expenditures | $3.49M | $2.92M | $3.37M | $5.28M | $3.67M | $6.00M | $9.09M | $6.43M | $8.19M | $1.88M |
| Free cash flow | -$3.24M | $7.60M | -$20.59M | $10.11M | $10.34M | $2.04M | $24.96M | $7.62M | $16.97M | $13.19M |
| Dividends paid | N/A | $918.00K | N/A | $7.25M | N/A | N/A | $0 | $0 | $0 | $0 |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $4.70M | N/A | $20.00M |
| Investing cash flow | -$2.94M | -$6.82M | $6.23M | -$25.24M | -$9.07M | $9.75M | -$23.50M | -$16.19M | -$55.47M | $16.69M |
| Financing cash flow | -$2.95M | $18.41M | -$375.00K | $10.23M | -$4.65M | -$11.03M | -$3.39M | -$6.51M | -$199.00K | -$19.68M |
Quarterly
| Line item | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.41M | $949.00K | -$7.89M | $3.66M | -$2.03M | $7.42M | -$8.79M | $1.25M | $25.89M | -$5.83M | -$10.80M |
| Capital expenditures | $501.00K | $319.00K | $302.00K | $542.00K | $959.00K | $1.27M | $720.00K | $748.00K | $470.00K | $723.00K | $977.00K |
| Free cash flow | $904.00K | $630.00K | -$8.20M | $3.12M | -$2.99M | $6.14M | -$9.51M | $502.00K | $25.42M | -$6.55M | -$11.78M |
Frequently Asked Questions About SRDX
What is SurModics' annual revenue?
SurModics reported revenue of $126.08M for the fiscal year ended Sep 30, 2024.
How fast is SurModics' revenue growing?
Revenue was down 4.9% for the fiscal year ended Sep 30, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was 6.2%.
Is SurModics profitable?
No. SurModics reported net income of -$11.54M for the fiscal year ended Sep 30, 2024, with a net margin of -9.2%.
How much free cash flow does SRDX generate?
For the fiscal year ended Sep 30, 2024, operating cash flow of $248.00K minus capital expenditures of $3.49M produced free cash flow of -$3.24M.
How much debt does SurModics have?
The balance sheet dated Sep 30, 2024 reported long-term debt of $29.55M and cash and equivalents of $36.12M.
SRDX pages: Overview, Financials